Assessment of serum periostin level as a predictor of requirement for intensive treatment for type-2 inflammation in asthmatics in future: A follow-up study of the KiHAC cohort
The need for a systematic approach for the management of un- controlled asthma has recently gained broad acceptance; these ap- proaches include strategies, such as revision of diagnosis, evaluation of adherence, and assessment of comorbidities. 1 This care pathway is pragmatically useful and can be improved even further by incorporating biomarkers that include asthma endo- types and phenotypes and predict the need for future high- intensity treatment for type-2 inflammation. Periostin is an extra- cellular matrix protein that is detected in serum 2,3 ; elevated levels of serum periostin have been associated with the Th2-type asthma phenotype/endotype, 4,5 and its stability is repeatedly reported. 6,7 Most intriguing is the possibility that serum periostin levels might predict the long-term prognosis of asthma currently managed with inhaled corticosteroid (ICS) treatment. Hereweassessed the useful- ness of serum periostin as a predictor of future treatment require- ments, notably the need for treatment intensification for type-2 inflammation.
展开▼
